Aclaris Q3 2026 Results: ATI-052 POC Trial in AD Showcased Rapid Improvement
The company reported positive Phase 1b results for ATI-052 in AD and asthma, with a strong cash runway extending through 2029; recent catalysts include the initiation of the Phase 2b modzatinib trial in lichen planus and Top Line results from the bosakitug Phase 2 ADMIRATION trial.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed